Antibiotic Therapies forClostridioides difficileInfection in Children
Open Access
- 1 November 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 10 (Supplement) , S52-S57
Abstract
While rates of Clostridioides difficile infection (CDI) are increasing among children in the United States, studies assessing CDI treatment in children are severely lacking. Thus, treatment guidelines have historically relied on evidence from limited observational data in children and randomized controlled trials (RCTs) conducted in adults to form recommendations. Currently, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare Epidemiology of America (SHEA) recommend metronidazole and/or vancomycin for pediatric CDI depending on disease severity. Recently however, the first and only RCT of CDI treatment in children demonstrated fidaxomicin to be non-inferior to vancomycin, proving its safety and efficacy in this population. Additionally, observational data published since the IDSA/SHEA guidelines were released suggest metronidazole has lower rates of clinical improvement when compared to vancomycin in hospitalized children with non-severe CDI. Given these recent publications, fidaxomicin and vancomycin, instead of metronidazole, appear to be more appropriate, evidence-based options for the treatment of CDI in children.Keywords
Funding Information
- Pfizer, Merck, and Azurity
This publication has 42 references indexed in Scilit:
- ComparativeIn VitroActivities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora IsolatesAntimicrobial Agents and Chemotherapy, 2013
- Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA SynthesisClinical Infectious Diseases, 2012
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trialThe Lancet Infectious Diseases, 2012
- A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infectionJournal of Antimicrobial Chemotherapy, 2011
- Clostridium difficile Infections among Hospitalized Children, United States, 1997–2006Emerging Infectious Diseases, 2010
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile InfectionAntimicrobial Agents and Chemotherapy, 2009
- In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficileAntimicrobial Agents and Chemotherapy, 2008
- Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficileAntimicrobial Agents and Chemotherapy, 2008
- Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral DosesAntimicrobial Agents and Chemotherapy, 2008
- Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and RifaximinClinical Infectious Diseases, 2007